Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

NCT01032070 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT01032070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01032070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
September 27, 2010
Completion date
November 26, 2012
Enrollment
25 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or refractory pediatric ependymoma